Kits
Thyroglobulin ELISA
Kits
Description
Thyroglobulin (TG), a glycoprotein with a molecular
weight of about 660,000 Daltons, is the thyroid’s
main iodine protein and the most important
compound of follicular colloid. Thyroglobulin is the
form under which the active hormones T3 and T4
together with their immediate forerunners MIT and
DIT are laid inside the thyroid gland. The clinical
applications of the TG dosage seem to originate
from its specificity for the thyroid and related cells.
The dosage of TG can be used as support to
scintigraphies or other techniques for studying
pathogenesis, making a diagnosis and analyzing the
course of thyroid disorders.
The dosage of TG before and after replacement
treatment with L-Thyroxin cannot be established in
cases of hypothyroidism due to thyroid agenesis. In
cases of secondary hypothyroidism with a
dysglandular goiter or ectopic thyroid, the levels of
TG are normal or high. The circulating levels of TG
tend to increase in several thyroid disorders such as
toxic and atoxic goiter, subacute thyroiditis,
Basedow’s disease and carcinoma. In Basedow’s
disease the TG dosage is a potentially interesting
index of normalization of hyperthyroidism in patients
treated with anti-thyroid drugs. In the oncology field
and more specifically for differentiated thyroid
carcinoma, there are very promising applications
linked to the ability of thyroid tumors tissues to
concentrate iodine and synthesize TG as a normal
thyroid. Basically the dosage of TG can be used as
follows:
a. Pre-operating diagnosis of thyroid tumors.
This application does not allow the differentiated
diagnosis of the tumor as the values of TG seen in
malignant and benign nodules are superimposable.
b. Post-operation monitoring
In patients treated surgically or with radiotherapy,
long lasting TG levels suggest the presence of a
residual carcinoma and/or carcinoma with
metastasis.
c. Monitoring of totally thyroidectomized patients
The use of circulating TG as an indicator of
recurrent tumors (metastasis marker) has an
established clinical value: the increase of
Thyroglobulinaemia indicates the need to undergo
further analysis for confirming the diagnosis.
Interesting advantages can come from: a) a reduced
use of scintigraphic diagnostic techniques as they
imply regular suspension of replacement treatment
and frequent exposure to radiation, b) and complete
completion of the information obtained via
scintigraphy
weight of about 660,000 Daltons, is the thyroid’s
main iodine protein and the most important
compound of follicular colloid. Thyroglobulin is the
form under which the active hormones T3 and T4
together with their immediate forerunners MIT and
DIT are laid inside the thyroid gland. The clinical
applications of the TG dosage seem to originate
from its specificity for the thyroid and related cells.
The dosage of TG can be used as support to
scintigraphies or other techniques for studying
pathogenesis, making a diagnosis and analyzing the
course of thyroid disorders.
The dosage of TG before and after replacement
treatment with L-Thyroxin cannot be established in
cases of hypothyroidism due to thyroid agenesis. In
cases of secondary hypothyroidism with a
dysglandular goiter or ectopic thyroid, the levels of
TG are normal or high. The circulating levels of TG
tend to increase in several thyroid disorders such as
toxic and atoxic goiter, subacute thyroiditis,
Basedow’s disease and carcinoma. In Basedow’s
disease the TG dosage is a potentially interesting
index of normalization of hyperthyroidism in patients
treated with anti-thyroid drugs. In the oncology field
and more specifically for differentiated thyroid
carcinoma, there are very promising applications
linked to the ability of thyroid tumors tissues to
concentrate iodine and synthesize TG as a normal
thyroid. Basically the dosage of TG can be used as
follows:
a. Pre-operating diagnosis of thyroid tumors.
This application does not allow the differentiated
diagnosis of the tumor as the values of TG seen in
malignant and benign nodules are superimposable.
b. Post-operation monitoring
In patients treated surgically or with radiotherapy,
long lasting TG levels suggest the presence of a
residual carcinoma and/or carcinoma with
metastasis.
c. Monitoring of totally thyroidectomized patients
The use of circulating TG as an indicator of
recurrent tumors (metastasis marker) has an
established clinical value: the increase of
Thyroglobulinaemia indicates the need to undergo
further analysis for confirming the diagnosis.
Interesting advantages can come from: a) a reduced
use of scintigraphic diagnostic techniques as they
imply regular suspension of replacement treatment
and frequent exposure to radiation, b) and complete
completion of the information obtained via
scintigraphy